137 related articles for article (PubMed ID: 37581458)
1. A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.
Linn SM; Novitzky-Basso I; Abduljalil O; Pasic I; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Kim DDH
Hematol Oncol Stem Cell Ther; 2023 Jul; 17(1):60-71. PubMed ID: 37581458
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
[TBL] [Abstract][Full Text] [Related]
5. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
Modi B; Hernandez-Henderson M; Yang D; Klein J; Dadwal S; Kopp E; Huelsman K; Mokhtari S; Ali H; Malki MMA; Spielberger R; Salhotra A; Zain J; Cotliar J; Parker P; Forman S; Nakamura R
Biol Blood Marrow Transplant; 2019 Feb; 25(2):265-269. PubMed ID: 30201397
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
9. The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease.
Alsuliman T; Magro L; Coiteux V; Gauthier J; Srour M; Lionet A; Beauvais D; Yakoub-Agha I
Curr Res Transl Med; 2020 Apr; 68(2):71-76. PubMed ID: 31631014
[TBL] [Abstract][Full Text] [Related]
10. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
12. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH
Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
14. Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease.
Choi JY; Kim H; Baek HJ; Kook H; Lee JM; Kim BK; An HY; Hong KT; Shin HY; Kang HJ
Transplant Cell Ther; 2021 Nov; 27(11):925.e1-925.e7. PubMed ID: 34314892
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
[TBL] [Abstract][Full Text] [Related]
17. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
[TBL] [Abstract][Full Text] [Related]
18. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.
Gagliardi TA; Milner J; Cairo MS; Steinberg A
Cureus; 2022 Sep; 14(9):e29195. PubMed ID: 36258935
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
Teusink-Cross A; Davies SM; Grimley MS; Chandra S; Flannery A; Dandoy CE; Nelson AS; Marsh RA; Jacoby B; Lane A; Khandelwal P
Pediatr Transplant; 2020 May; 24(3):e13692. PubMed ID: 32202691
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.
Zhao JY; Liu SN; Xu LP; Zhang XH; Wang Y; Chen YH; Liu KY; Huang XJ; Mo XD
Ann Hematol; 2021 Jan; 100(1):169-180. PubMed ID: 33159239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
